NCT07007962View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

November 5, 2027

Study Completion Date

December 30, 2028

Conditions
Immune Thrombocytopenia
Interventions
DRUG

rilzabrutinib

Pharmaceutical form:Tablet-Route of administration:Oral

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT07007962 - Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment | Biotech Hunter | Biotech Hunter